SG10202105790QA - Antibodies binding to cd3 - Google Patents

Antibodies binding to cd3

Info

Publication number
SG10202105790QA
SG10202105790QA SG10202105790QA SG10202105790QA SG10202105790QA SG 10202105790Q A SG10202105790Q A SG 10202105790QA SG 10202105790Q A SG10202105790Q A SG 10202105790QA SG 10202105790Q A SG10202105790Q A SG 10202105790QA SG 10202105790Q A SG10202105790Q A SG 10202105790QA
Authority
SG
Singapore
Prior art keywords
antibodies binding
antibodies
binding
Prior art date
Application number
SG10202105790QA
Other languages
English (en)
Inventor
Anne Freimoser-Grundschober
Thomas Hofer
Ralf Hosse
Ekkehard Moessner
Valeria G Nicolini
Pablo Umaña
Inja Waldhauer
Wolfgang Richter
Alexander Knaupp
Halina Trochanowska
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of SG10202105790QA publication Critical patent/SG10202105790QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Impression-Transfer Materials And Handling Thereof (AREA)
SG10202105790QA 2018-12-21 2019-12-19 Antibodies binding to cd3 SG10202105790QA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18214994 2018-12-21

Publications (1)

Publication Number Publication Date
SG10202105790QA true SG10202105790QA (en) 2021-07-29

Family

ID=64755342

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10202105790QA SG10202105790QA (en) 2018-12-21 2019-12-19 Antibodies binding to cd3
SG10202105788SA SG10202105788SA (en) 2018-12-21 2019-12-19 Antibodies binding to cd3
SG11202102859TA SG11202102859TA (en) 2018-12-21 2019-12-19 Antibodies binding to cd3

Family Applications After (2)

Application Number Title Priority Date Filing Date
SG10202105788SA SG10202105788SA (en) 2018-12-21 2019-12-19 Antibodies binding to cd3
SG11202102859TA SG11202102859TA (en) 2018-12-21 2019-12-19 Antibodies binding to cd3

Country Status (19)

Country Link
US (4) US11672858B2 (zh)
EP (1) EP3897847A1 (zh)
JP (1) JP7061733B2 (zh)
CN (3) CN113195056B (zh)
AR (1) AR117727A1 (zh)
AU (2) AU2019410075B2 (zh)
BR (1) BR112021011939A2 (zh)
CA (1) CA3115020A1 (zh)
CL (2) CL2021001506A1 (zh)
CO (2) CO2021008568A2 (zh)
CR (2) CR20210330A (zh)
IL (1) IL283939A (zh)
MA (1) MA54514A (zh)
MX (1) MX2021007307A (zh)
MY (1) MY194642A (zh)
PE (1) PE20211603A1 (zh)
SG (3) SG10202105790QA (zh)
TW (3) TWI829831B (zh)
WO (1) WO2020127619A1 (zh)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010115589A1 (en) 2009-04-07 2010-10-14 Roche Glycart Ag Trivalent, bispecific antibodies
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
JP6721590B2 (ja) * 2014-12-03 2020-07-15 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 多重特異性抗体
EP3897847A1 (en) 2018-12-21 2021-10-27 F. Hoffmann-La Roche AG Antibodies binding to cd3
PE20220394A1 (es) * 2019-07-31 2022-03-18 Hoffmann La Roche Anticuerpos que se fijan a gprc5d
CR20220637A (es) 2020-06-19 2023-01-31 Hoffmann La Roche Anticuerpos que se unen a cd3 y cd19
WO2021255146A1 (en) * 2020-06-19 2021-12-23 F. Hoffmann-La Roche Ag Antibodies binding to cd3 and cea
KR20230025673A (ko) * 2020-06-19 2023-02-22 에프. 호프만-라 로슈 아게 CD3 및 FolR1에 결합하는 항체
CA3176579A1 (en) * 2020-06-19 2021-12-23 F. Hoffmann-La Roche Ag Antibodies binding to cd3
JP2023529982A (ja) * 2020-06-19 2023-07-12 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト プロテアーゼ活性化型ｔ細胞二重特異性抗体
JP7326584B2 (ja) 2020-12-17 2023-08-15 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗ｈｌａ－ｇ抗体及びその使用
US20220229062A1 (en) * 2021-01-21 2022-07-21 Diagnostic Biosystems Method for rapid immunohistochemical detection of an antigen from a biological sample
EP4304724A1 (en) * 2021-03-09 2024-01-17 F. Hoffmann-La Roche AG Combination therapy of pd-1-targeted il-2 variant immunoconjugate and anti-tyrp1/anti-cd3 bispecific antibodies
EP4355778A1 (en) 2021-06-17 2024-04-24 Boehringer Ingelheim International GmbH Novel tri-specific binding molecules
EP4437006A1 (en) 2021-11-26 2024-10-02 F. Hoffmann-La Roche AG Combination therapy of anti-tyrp1/anti-cd3 bispecific antibodies and tyrp1-specific antibodies
AR127887A1 (es) 2021-12-10 2024-03-06 Hoffmann La Roche Anticuerpos que se unen a cd3 y plap
WO2024027120A1 (en) * 2022-08-05 2024-02-08 Shanghai Kaijin Biotechnology , Ltd Multi-specific polypeptide complexes
WO2024040127A2 (en) * 2022-08-16 2024-02-22 Northwestern University Anti-tyrp1 bi-specific t cell engaging protein for treatment of tyrp1-expressing melanoma
WO2024088987A1 (en) 2022-10-26 2024-05-02 F. Hoffmann-La Roche Ag Combination therapy for the treatment of cancer
WO2024156672A1 (en) 2023-01-25 2024-08-02 F. Hoffmann-La Roche Ag Antibodies binding to csf1r and cd3
WO2024184287A1 (en) 2023-03-06 2024-09-12 F. Hoffmann-La Roche Ag Combination therapy of an anti-egfrviii/anti-cd3 antibody and an tumor-targeted 4-1bb agonist

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US830930A (en) 1905-11-22 1906-09-11 E & T Fairbanks & Co Weighing-scale.
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
ATE196606T1 (de) 1992-11-13 2000-10-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörpern, die gegen ein differenzierung-antigen gerichtet sind, dessen expression auf menschliche b lymphozyt beschränkt ist, für die behandlung von b-zell-lymphoma
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
DK0979281T3 (da) 1997-05-02 2005-11-21 Genentech Inc Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele
ATE296315T1 (de) 1997-06-24 2005-06-15 Genentech Inc Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
EP1028751B1 (en) 1997-10-31 2008-12-31 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
DK1034298T3 (da) 1997-12-05 2012-01-30 Scripps Research Inst Humanisering af murint antistof
AU3657899A (en) 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
US20030175884A1 (en) 2001-08-03 2003-09-18 Pablo Umana Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
WO2001007611A2 (en) 1999-07-26 2001-02-01 Genentech, Inc. Novel polynucleotides and method for the use thereof
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
NZ517906A (en) 1999-10-04 2003-01-31 Medicago Inc Cloning of genomic sequences encoding nitrite reductase (NiR) for use in regulated expression of foreign genes in host plants
DK2857516T3 (en) 2000-04-11 2017-08-07 Genentech Inc Multivalent antibodies and uses thereof
HUP0600342A3 (en) 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
JP4628679B2 (ja) 2002-04-09 2011-02-09 協和発酵キリン株式会社 Ｇｄｐ−フコースの輸送に関与する蛋白質の活性が低下または欠失した細胞
JP4832719B2 (ja) 2002-04-09 2011-12-07 協和発酵キリン株式会社 ＦｃγＲＩＩＩａ多型患者に適応する抗体組成物含有医薬
WO2003085118A1 (fr) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Procede de production de composition anticorps
CA2481658A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to fcy receptor iiia
PL373256A1 (en) 2002-04-09 2005-08-22 Kyowa Hakko Kogyo Co, Ltd. Cells with modified genome
EP2301966A1 (en) 2002-12-16 2011-03-30 Genentech, Inc. Immunoglobulin variants and uses thereof
ES2542885T3 (es) 2003-01-22 2015-08-12 Roche Glycart Ag Constructos de fusión y uso de los mismos para producir anticuerpos con mayor afinidad de unión al receptor de Fc y función efectora
EP1629012B1 (en) 2003-05-31 2018-11-28 Amgen Research (Munich) GmbH Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
WO2005097832A2 (en) 2004-03-31 2005-10-20 Genentech, Inc. Humanized anti-tgf-beta antibodies
EP2357201B1 (en) 2004-04-13 2017-08-30 F. Hoffmann-La Roche AG Anti-P-selectin antibodies
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
NZ553500A (en) 2004-09-23 2009-11-27 Genentech Inc Genentech Inc Cysteine engineered antibodies and conjugates withCysteine engineered antibodies and conjugates with a free cysteine amino acid in the heavy chain a free cysteine amino acid in the heavy chain
SI1871805T1 (sl) 2005-02-07 2020-02-28 Roche Glycart Ag Antigen vezavne molekule, ki vežejo EGFR, vektorji, ki te kodirajo in uporabe le-teh
EP1870459B1 (en) 2005-03-31 2016-06-29 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
EP3178850B1 (en) 2005-10-11 2021-01-13 Amgen Research (Munich) GmbH Compositions comprising cross-species-specific antibodies and uses thereof
JP5474531B2 (ja) 2006-03-24 2014-04-16 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 操作されたヘテロ二量体タンパク質ドメイン
US20090182127A1 (en) 2006-06-22 2009-07-16 Novo Nordisk A/S Production of Bispecific Antibodies
US20080044455A1 (en) 2006-08-21 2008-02-21 Chaim Welczer Tonsillitus Treatment
EP2471816A1 (en) 2006-08-30 2012-07-04 Genentech, Inc. Multispecific antibodies
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
WO2008119567A2 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific cd3-epsilon binding domain
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
HUE028536T2 (en) 2008-01-07 2016-12-28 Amgen Inc Method for producing antibody to FC heterodimer molecules using electrostatic control effects
SG175004A1 (en) 2009-04-02 2011-11-28 Roche Glycart Ag Multispecific antibodies comprising full length antibodies and single chain fab fragments
WO2010115589A1 (en) 2009-04-07 2010-10-14 Roche Glycart Ag Trivalent, bispecific antibodies
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
PE20120540A1 (es) 2009-05-27 2012-05-09 Hoffmann La Roche Anticuerpos triespecificos o tetraespecificos
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
RU2573915C2 (ru) 2009-09-16 2016-01-27 Дженентек, Инк. Содержащие суперспираль и/или привязку белковые комплексы и их применение
PL2519543T3 (pl) 2009-12-29 2016-12-30 Białka wiążące heterodimery i ich zastosowania
JP6022444B2 (ja) 2010-05-14 2016-11-09 ライナット ニューロサイエンス コーポレイション ヘテロ二量体タンパク質ならびにそれを生産および精製するための方法
EP2579897A1 (en) 2010-06-08 2013-04-17 Genentech, Inc. Cysteine engineered antibodies and conjugates
DK2635607T3 (da) 2010-11-05 2019-11-18 Zymeworks Inc Stabilt heterodimert antistofdesign med mutationer i fc-domænet
ES2692268T3 (es) 2011-03-29 2018-12-03 Roche Glycart Ag Variantes de Fc de anticuerpo
WO2013026839A1 (en) 2011-08-23 2013-02-28 Roche Glycart Ag Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
RS57744B1 (sr) 2011-08-23 2018-12-31 Roche Glycart Ag Bispecifični antigen vezujući molekuli
NO2748201T3 (zh) 2011-08-23 2018-05-12
EP2794905B1 (en) 2011-12-20 2020-04-01 MedImmune, LLC Modified polypeptides for bispecific antibody scaffolds
MX360352B (es) 2012-02-15 2018-10-30 Hoffmann La Roche Cromatografia de afinidad basada en receptores fc.
EA035344B1 (ru) 2012-04-20 2020-05-29 Мерюс Н.В. Способ получения двух антител из одной клетки-хозяина
WO2013166594A1 (en) * 2012-05-10 2013-11-14 Zymeworks Inc. Heteromultimer constructs of immunoglobulin heavy chains with mutations in the fc domain
CA2896370A1 (en) 2013-02-26 2014-09-04 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
KR102282761B1 (ko) 2013-02-26 2021-07-30 로슈 글리카트 아게 이중특이적 t 세포 활성화 항원 결합 분자
CN105555804B (zh) * 2013-08-07 2020-12-25 阿菲姆德股份有限公司 对EGFRvIII有特异性的抗体结合位点
JP7325166B2 (ja) 2013-12-20 2023-08-14 ジェネンテック， インコーポレイテッド 二重特異性抗体
UA117289C2 (uk) 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
CN106573986A (zh) 2014-07-29 2017-04-19 豪夫迈·罗氏有限公司 多特异性抗体
CN107074973A (zh) * 2014-07-29 2017-08-18 辉瑞大药厂 用于癌症免疫疗法的EGFRvIII特异性嵌合抗原受体
EP3174901B1 (en) * 2014-07-31 2019-06-26 Amgen Research (Munich) GmbH Optimized cross-species specific bispecific single chain antibody constructs
KR102317315B1 (ko) 2014-08-04 2021-10-27 에프. 호프만-라 로슈 아게 이중특이적 t 세포 활성화 항원 결합 분자
AR101844A1 (es) 2014-09-12 2017-01-18 Genentech Inc Anticuerpos y conjugados modificados genéticamente con cisteína
EP3789402B1 (en) * 2014-11-20 2022-07-13 F. Hoffmann-La Roche AG Combination therapy of t cell activating bispecific antigen binding molecules and pd-1 axis binding antagonists
JP7146395B2 (ja) 2014-11-20 2022-10-04 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト ＦｏｌＲ１及びＣＤ３を標的とする二重特異性抗体
AU2016252773B2 (en) 2015-04-24 2022-06-02 Genentech, Inc. Multispecific antigen-binding proteins
TWI744242B (zh) * 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
WO2017055318A1 (en) * 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Cd33xcd3 bispecific t cell activating antigen binding molecules
AR106365A1 (es) * 2015-10-02 2018-01-10 Hoffmann La Roche Moléculas biespecíficas de unión a antígeno activadoras de células t
WO2017055393A1 (en) * 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Anti-cd3xtim-3 bispecific t cell activating antigen binding molecules
JP7044700B2 (ja) * 2015-10-02 2022-03-30 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 二重特異性抗ｃｅａｘｃｄ３ ｔ細胞活性化抗原結合分子
JP2018533930A (ja) * 2015-10-02 2018-11-22 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 二重特異性ｔ細胞活性化抗原結合分子
MX2018005036A (es) 2015-10-29 2018-08-01 Hoffmann La Roche Anticuerpos y metodos de uso de anti-regiones de fragmentos cristalizables (fc) variantes.
NZ744821A (en) * 2016-01-21 2023-06-30 Pfizer Chimeric antigen receptors targeting epidermal growth factor receptor variant iii
WO2018223004A1 (en) * 2017-06-01 2018-12-06 Xencor, Inc. Bispecific antibodies that bind cd20 and cd3
SG11202105093RA (en) 2018-12-21 2021-06-29 Hoffmann La Roche Tumor-targeted agonistic cd28 antigen binding molecules
EP3897847A1 (en) 2018-12-21 2021-10-27 F. Hoffmann-La Roche AG Antibodies binding to cd3
PE20220394A1 (es) 2019-07-31 2022-03-18 Hoffmann La Roche Anticuerpos que se fijan a gprc5d
KR20230025673A (ko) 2020-06-19 2023-02-22 에프. 호프만-라 로슈 아게 CD3 및 FolR1에 결합하는 항체
CR20220637A (es) 2020-06-19 2023-01-31 Hoffmann La Roche Anticuerpos que se unen a cd3 y cd19
CN115916827A (zh) 2020-06-19 2023-04-04 豪夫迈·罗氏有限公司 免疫活化Fc结构域结合分子
WO2021255146A1 (en) 2020-06-19 2021-12-23 F. Hoffmann-La Roche Ag Antibodies binding to cd3 and cea
JP7326584B2 (ja) 2020-12-17 2023-08-15 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗ｈｌａ－ｇ抗体及びその使用

Also Published As

Publication number Publication date
TWI829831B (zh) 2024-01-21
SG10202105788SA (en) 2021-06-29
AU2019410075A1 (en) 2021-04-15
IL283939A (en) 2021-07-29
US20240042022A1 (en) 2024-02-08
CR20210325A (es) 2021-07-20
TW202428614A (zh) 2024-07-16
TWI818387B (zh) 2023-10-11
CN118271445A (zh) 2024-07-02
WO2020127619A1 (en) 2020-06-25
JP2022513493A (ja) 2022-02-08
AU2019410075B2 (en) 2022-08-25
CO2021011065A2 (es) 2021-09-09
CO2021008568A2 (es) 2021-07-30
CN113195056A (zh) 2021-07-30
SG11202102859TA (en) 2021-04-29
KR20210094588A (ko) 2021-07-29
MY194642A (en) 2022-12-09
AR117727A1 (es) 2021-08-25
US20200270347A1 (en) 2020-08-27
US20230277662A1 (en) 2023-09-07
TW202039566A (zh) 2020-11-01
US20210403562A1 (en) 2021-12-30
JP7061733B2 (ja) 2022-04-28
MA54514A (fr) 2022-03-30
CN113621062A (zh) 2021-11-09
EP3897847A1 (en) 2021-10-27
CR20210330A (es) 2021-07-20
CN113195056B (zh) 2024-05-07
BR112021011939A2 (pt) 2021-09-14
AU2022206732A1 (en) 2022-09-29
MX2021007307A (es) 2021-07-07
CA3115020A1 (en) 2020-06-25
CL2021003132A1 (es) 2022-08-19
TW202212361A (zh) 2022-04-01
US11672858B2 (en) 2023-06-13
US11591397B2 (en) 2023-02-28
CL2021001506A1 (es) 2021-12-24
PE20211603A1 (es) 2021-08-18
CN113621062B (zh) 2024-07-02

Similar Documents

Publication Publication Date Title
IL283939A (en) Antibodies bind to cd3
IL276537A (en) Antibodies bind to GPRC5D
ZA202203250B (en) Cd3 binding antibodies
IL263840A (en) cd3 binding antibodies
IL287613A (en) Antibodies that bind gprc5d
HRP20181802T1 (hr) Protutijela koja vežu humani cd3
IL279894A (en) Antibodies that bind to ilt4
IL253569A0 (en) Antibodies against 3cd, antibodies against 23cd, and B-specific antibodies that specifically bind to 3cd or 23cd
IL256870B (en) Constructs for bispecific antibodies that bind to CD70 and CD3 and uses thereof
IL256872A (en) Bispecific antibody constructs that bind to egfrviii and cd3 and uses thereof
AU2016210068A1 (en) Anti-CD3 antibodies, anti-CD123 antibodies and bispecific antibodies specifically binding to CD3 and/or CD123
IL269394A (en) Antibodies bind to STEAP-1
ZA202104356B (en) Monoclonal antibodies that bind specifically to human trbv9
SG11202106990PA (en) BISPECIFIC ANTIBODY BINDING TO TfR